Nicola Trevor
Overview
Explore the profile of Nicola Trevor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tervonen T, Duenas A, Collacott H, Lam A, Gries K, Carson R, et al.
Value Health
. 2023 Feb;
26(6):909-917.
PMID: 36738785
Objectives: To examine how disease status and current health state influence treatment preferences of patients with multiple myeloma (MM). Methods: Participants with MM from France, Germany, and the United Kingdom...
2.
van Hest N, Morten P, Stubbs K, Trevor N
J Health Econ Outcomes Res
. 2023 Jan;
10(1):1-9.
PMID: 36688213
Demonstrating the cost-effectiveness of new treatments for multiple myeloma (MM) often relies on the extrapolation of overall survival (OS) trial data. This method can introduce uncertainty in long-term survival estimates...
3.
He J, Duenas A, Collacott H, Lam A, Gries K, Carson R, et al.
Patient
. 2021 Mar;
14(5):613-623.
PMID: 33686594
Background: The current standard of care for multiple myeloma requires several regimens of treatment, with patients experiencing high symptom burden and side effects, which negatively impact health-related quality of life...
4.
Edwards S, Karner C, Trevor N, Wakefield V, Salih F
Health Technol Assess
. 2015 Aug;
19(65):1-210.
PMID: 26293406
Background: Bradycardia [resting heart rate below 60 beats per minute (b.p.m.)] can be caused by conditions affecting the natural pacemakers of the heart, such as sick sinus syndrome (SSS) and...
5.
Edwards S, Barton S, Thurgar E, Trevor N
Health Technol Assess
. 2015 Jan;
19(7):1-480.
PMID: 25626481
Background: Ovarian cancer is the fifth most common cancer in the UK, and the fourth most common cause of cancer death. Of those people successfully treated with first-line chemotherapy, 55-75%...
6.
Greenhalgh J, Bagust A, Boland A, Oyee J, Trevor N, Beale S, et al.
Pharmacoeconomics
. 2014 Sep;
33(2):137-48.
PMID: 25213036
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Eisai Ltd) to submit evidence for the clinical and cost effectiveness of eribulin as treatment for...